CONTEXT: This review focuses on the most widely used risk stratification and prediction tools for non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To assess the clinical use and relevance of risk stratification and prediction tools to enhance clinical decision making and counselling of patients with NMIBC. EVIDENCE ACQUISITION: The most frequent, currently used risk stratification tools and prognostic models for NMIBC patients were identified by the members of the European Association of Urology (EAU) Guidelines Panel on NMIBC. EVIDENCE SYNTHESIS: The 2006 European Organization for Research and Treatment of Cancer (EORTC) risk tables are the most widely used and validated tools for risk stratification and prognosis prediction in NMIBC patients. The EAU risk categories constitute a simple alternative to the EORTC risk tables and can be used for comparable risk stratification. In the subgroup of NMIBC patients treated with a short maintenance schedule of bacillus Calmette-Guerin (BCG), the Club Urológico Español de Tratamiento Oncológico (CUETO) scoring model is more accurate than the EORTC risk tables. Both the EORTC risk tables and the CUETO scoring model overestimate the recurrence and progression risks in patients treated according to current guidelines. The new concept of conditional recurrence and progression estimates is very promising during follow-up but should be validated. CONCLUSIONS: Risk stratification and prognostic models enable outcome comparisons and standardisation of treatment and follow-up. At present, none of the available risk stratification and prognostic models reflects current standards of treatment. The EORTC risk tables and CUETO scoring model should be updated with previously unavailable data and recalculated. PATIENT SUMMARY: Non-muscle-invasive bladder cancer is a heterogeneous disease. A risk-based therapeutic approach is recommended. We present available risk stratification and prediction tools and the degree of their validation with the aim to increase their use in everyday clinical practice.

Academic Urology Unit University of Aberdeen Scotland UK

Department of Medicine Health Science Centre McMaster University Hamilton Ontario Canada

Department of Pathology Hôpital Tenon Assistance Publique Hopitaux de Paris Institut Universitaire de Cancérologie GRC5 Sorbonne University Paris France

Department of Surgical Oncology Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands

Department of Surgical Sciences Urology University of Turin Turin Italy

Department of Urology and Paediatric Urology Julius Maximilians University Würzburg Würzburg Germany

Department of Urology Fundació Puigvert Universitat Autònoma de Barcelona Barcelona Spain

Department of Urology General Teaching Hospital and 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Department of Urology Hopital Pitié Salpêtrière Assistance Publique Hôpitaux de Paris Institut Universitaire de Cancérologie GRC5 Sorbonne University Paris France

Department of Urology Hospital Universitario Fundación de Alcorcón Madrid Spain

Department of Urology Medizinische Universität Graz Graz Austria

Department of Urology Motol University Hospital and 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Royal Free London NHS Foundation Trust London UK

Department of Urology Royal Surrey County Hospital Guildford UK

Department of Urology Vienna General Hospital Medical University of Vienna Vienna Austria

EAU Guidelines Office Board European Association of Urology Arnhem The Netherlands

References provided by Crossref.org

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer

Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets